Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 23, 2024
Event: Entry into a Material Definitive Agreement and creation of a direct financial obligation via a convertible promissory note.
Key Financial Metrics
This filing details a specific financing transaction rather than periodic financial performance. Key metrics related to the transaction include:
- Principal Amount: $33,000
- Purchase Price (Net Proceeds): $30,000
- Interest Rate: 8% per annum (increases to 24% upon Event of Default)
- Maturity Date: March 25, 2025
- Use of Proceeds: General working capital
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, or total debt liquidity positions outside of this specific transaction.
Material Changes and Transaction Terms
The Company entered into a Securities Purchase Agreement with an investor for a convertible promissory note. Material terms include:
- Conversion Rights:
- Fixed Price: $0.0003 per share.
- Price Adjustment: If the stock trades below $0.0003 for more than 5 consecutive trading days, the price adjusts to $0.0001 per share.
- Default Adjustment: In the event of default, the conversion price becomes the lowest trading price over the prior 10 trading days, re-adjusted every 30 days if default persists.
- Prepayment Penalties:
- First 60 days: 110% of face amount plus accrued interest.
- Days 61-120: 120% of face amount plus accrued interest.
- Days 121-180: 125% of face amount plus accrued interest.
- After 180 days: No right to prepay.
- Events of Default: Include failure to pay, failure to issue shares, failure to maintain OTC listing, failure to comply with SEC reporting, insolvency, or bankruptcy. Default triggers immediate due and payable status and interest rate increase.
Guidance, Risks, and Contingencies
Management Commentary: The Company intends to use the net proceeds for general working capital purposes.
Risks and Contingencies:
- Dilution Risk: The note includes significant downside protection for the investor via price adjustments to $0.0001 or the lowest trading price in default scenarios, which could result in substantial dilution to existing shareholders.
- Liquidity Constraints: The Company cannot prepay the note after the initial 180-day period, locking in the debt obligation until maturity.
- Compliance Risk: Failure to maintain OTC listing or SEC reporting compliance constitutes an immediate event of default.
Investor Verification Checklist
- Verify the current trading price of Propanc Biopharma common stock to assess the likelihood of the conversion price adjusting to $0.0001.
- Confirm the Company's current cash position to evaluate the ability to service the 8% interest and potential prepayment penalties.
- Review the Company's recent SEC filing history to ensure no existing defaults on reporting requirements that could trigger immediate acceleration of this note.
- Check the OTC Markets status to confirm the stock remains listed and quoted.
- Examine the full text of the Convertible Promissory Note (Exhibit 4.1) for additional covenants not summarized in the 8-K.